Kalydeco Vertex Pharmaceuticals Australia Pty Ltd
Product name
Kalydeco
Accepted date
Apr-2024
Active ingredients
ivacaftor
Proposed indication
For the treatment of cystic fibrosis.
Application type
C (new indication)
Publication date
Apr-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.